Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRM003
MIFTS: 54

Tremor

Categories: Genetic diseases, Rare diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Tremor

About this section

MalaCards integrated aliases for Tremor:

Name: Tremor 54 29 6 43
Tremors 6

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

ICD10 33 R25.1
Sources

Summaries for Tremor

About this section
NINDS : 54 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

MalaCards based summary : Tremor, also known as tremors, is related to parkinson disease 15, autosomal recessive early-onset and multiple system atrophy 1. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Lidocaine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are behavior/neurological and cardiovascular system

MedlinePlus : 43 Tremors are unintentional trembling or shaking movements in one or more parts of your body. Most tremors occur in the hands. You can also have arm, head, face, vocal cord, trunk, and leg tremors. Tremors are most common in middle-aged and older people, but anyone can have them. The cause of tremors is a problem in the parts of the brain that control muscles in the body or in specific parts of the body, such as the hands. They commonly occur in otherwise healthy people. They may also be caused by problems such as Parkinson's disease Dystonia Multiple sclerosis Stroke Traumatic brain injury Alcohol abuse and withdrawal Certain medicines Some forms are inherited and run in families. Others have no known cause. There is no cure for most tremors. Treatment to relieve them depends on their cause. In many cases, medicines and sometimes surgical procedures can reduce or stop tremors and improve muscle control. Tremors are not life threatening. However, they can be embarrassing and make it hard to perform daily tasks. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Sources

Related Diseases for Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 15, autosomal recessive early-onset 31.1 C19orf12 SNCA
2 multiple system atrophy 1 30.9 LRRK2 MAPT PRKN SNCA
3 restless legs syndrome 29.9 DRD3 PRKN SNCA
4 essential tremor 29.9 DNAJC13 DRD3 FMR1 FUS HTRA2 LRRK2
5 rem sleep behavior disorder 29.6 LRRK2 SNCA
6 parkinson disease 2, autosomal recessive juvenile 29.4 HTRA2 LRRK2 PRKN SNCA
7 neuronal intranuclear inclusion disease 29.3 MAPT SNCA
8 neurodegeneration with brain iron accumulation 1 29.3 C19orf12 SNCA
9 parkinson disease, late-onset 29.2 DNAJC13 DRD3 GBA LRRK2 MAPT PRKN
10 movement disease 29.1 DRD3 FMR1 GBA LRRK2 MAPT PRKN
11 motor neuron disease 29.1 FUS MAPT SNCA
12 supranuclear palsy, progressive, 1 28.7 LRRK2 MAPT PRKN SNCA
13 niemann-pick disease, type c1 28.5 MAPT SNCA
14 dementia 28.1 FUS GBA LRRK2 MAPT PRKN SNCA
15 primary orthostatic tremor 12.4
16 fragile x tremor/ataxia syndrome 12.3
17 fragile x-associated tremor/ataxia syndrome 12.3
18 tremor, hereditary essential, 1 12.2
19 tremor, hereditary essential, 4 12.2
20 tremor, hereditary essential, 5 12.2
21 tremor, hereditary essential, 2 12.0
22 tremor, nystagmus, and duodenal ulcer 11.9
23 tremor, hereditary essential, 3 11.9
24 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 11.8
25 sensorineural hearing loss-early graying-essential tremor syndrome 11.8
26 tremor of intention, ataxia, and lipofuscinosis 11.8
27 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.7
28 epilepsy, familial adult myoclonic, 5 11.5
29 epilepsy, familial adult myoclonic, 2 11.5
30 mental retardation, x-linked, syndromic, cabezas type 11.4
31 epilepsy, familial adult myoclonic, 1 11.4
32 myoclonic cerebellar dyssynergia 11.4
33 psychogenic movement 11.3
34 mental retardation, autosomal recessive 48 11.3
35 hereditary geniospasm 11.3
36 dystonia 11.3
37 hypertrophic olivary degeneration 11.2
38 multiple sclerosis 11.1
39 cerebellar degeneration 11.1
40 focal dystonia 11.1
41 central pontine myelinolysis 11.1
42 roussy-levy hereditary areflexic dystasia 11.0
43 spinocerebellar ataxia 6 11.0
44 japanese encephalitis 11.0
45 dystonia 12 11.0
46 cervical dystonia 11.0
47 aceruloplasminemia 11.0
48 epilepsy, familial adult myoclonic, 3 10.9
49 epilepsy, familial adult myoclonic, 4 10.9
50 neurodegeneration with brain iron accumulation 10.9

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor
Sources

Symptoms & Phenotypes for Tremor

About this section

MGI Mouse Phenotypes related to Tremor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 CNTN2 DRD3 FMR1 GBA HTRA2 LRRK2
2 cardiovascular system MP:0005385 9.86 DRD3 GBA HTRA2 LRRK2 MAPT PRKN
3 cellular MP:0005384 9.76 PRKN SNCA TENM4 FMR1 GBA HTRA2
4 integument MP:0010771 9.5 FMR1 GBA HTRA2 LRRK2 MAPT PRKN
5 nervous system MP:0003631 9.32 FMR1 GBA HTRA2 LRRK2 MAPT PRKN
Sources

Drugs & Therapeutics for Tremor

About this section

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 483)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 137-58-6 3676
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
5
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
7
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
8
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1 106266-06-2 5073
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 22916-47-8 4189
10
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
11
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
12
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 525-66-6 4946
13
Donepezil Approved Phase 4 120014-06-4 3152
14
Oxytocin Approved, Vet_approved Phase 4,Phase 2 50-56-6 439302 53477758
15
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
16
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 23994
17
alemtuzumab Approved, Investigational Phase 4 216503-57-0
18
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754
20
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
21
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
22
Gliclazide Approved Phase 4,Phase 3 21187-98-4 3475
23
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
24
Carbidopa Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28860-95-9 34359 38101
25
Methadone Approved Phase 4,Phase 3,Phase 1 76-99-3 4095
26
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
27
Phentermine Approved, Illicit Phase 4,Not Applicable 122-09-8 4771
28 Piracetam Approved, Investigational Phase 4,Phase 1,Phase 2 7491-74-9
29
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
30
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
31
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
32
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 148553-50-8 5486971
33
Bambuterol Approved, Investigational Phase 4 81732-65-2, 81732-46-9 54766
34
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 59868 119570
35
Entacapone Approved, Investigational Phase 4,Phase 3 130929-57-6 5281081
36
Rasagiline Approved Phase 4,Phase 3,Phase 2 136236-51-6 3052776
37
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
38
Daptomycin Approved, Investigational Phase 4,Phase 3 103060-53-3 16129629
39
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
40
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-92-7 6047
41
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
42
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
43
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
44
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
45
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
46
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
47
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Phase 2 51-43-4 5816
48
Terbutaline Approved Phase 4 23031-25-6 5403
49
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
50
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3 90566-53-3 62924

Interventional clinical trials:

(show top 50) (show all 703)
# Name Status NCT ID Phase Drugs
1 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
2 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance Unknown status NCT02329379 Phase 4 Levothyroxine
5 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
6 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
7 ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery Unknown status NCT01579201 Phase 4 Carbetocin
8 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
9 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
10 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
11 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
12 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
13 Treatment of Pendular Nystagmus in OPT Completed NCT02466191 Phase 4 Memantine;Gabapentin
14 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
15 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
16 Effects of a Nutritional Supplement Combination on Body Weight Management Completed NCT01725958 Phase 4
17 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
18 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
19 Aerosolized Beta-Agonist Isomers in Asthma Completed NCT02170532 Phase 4 levalbuterol;saline;ipratroprium
20 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
21 Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room Completed NCT01091337 Phase 4 Procaterol;Salbutamol
22 Treatment of Bipolar Mania in Older Adults Completed NCT00254488 Phase 4 Lithium (LI);Divalproex (DV)
23 Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
24 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
25 QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Completed NCT03045133 Phase 4 Methadone;Morphine
26 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
27 A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease Completed NCT01494532 Phase 4 ropinirole/L-dopa;placebo/L-dopa
28 Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
29 Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler Completed NCT02416180 Phase 4
30 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
31 Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
32 The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet Completed NCT00138645 Phase 4
33 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants Completed NCT02233985 Phase 4 0.9% Sodium Chloride;3% Sodium Chloride
34 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed NCT00208091 Phase 4 Botulinum toxin, type B
35 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
36 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) Completed NCT01728376 Phase 4 Daptomycin;Comparator
37 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
38 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
39 Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients Completed NCT01796730 Phase 4 bambuterol;Placebo
40 A Toolbox Approach to Obesity Treatment in Primary Care Completed NCT01922934 Phase 4 Obesity pharmacotherapy
41 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Completed NCT00141518 Phase 4 Levodopa-carbidopa intestinal gel (LCIG)
42 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
43 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
44 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
45 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
46 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
47 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
48 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
49 SALT Study (Switching to the Administration of Lithium Slow -Release Treatment) Recruiting NCT03210480 Phase 4 Lithium sulphate prolonged-release 660 mg;Lithium carbonate immediate-release 150 mg and 300 mg
50 CNS Study of Patients Switching From Tacrolimus to Envarsus Recruiting NCT03270462 Phase 4 Envarsus XR

Search NIH Clinical Center for Tremor

Sources

Genetic Tests for Tremor

About this section

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29
Sources

Anatomical Context for Tremor

About this section

MalaCards organs/tissues related to Tremor:

41
Brain, Eye, Testes, Tongue, Thyroid, Cerebellum, Thalamus
Sources

Publications for Tremor

About this section

Articles related to Tremor:

(show top 50) (show all 1615)
# Title Authors Year
1
Complete Resolution of Symptoms of Primary Orthostatic Tremor with Perampanel. ( 29686940 )
2018
2
Caffeine Consumption in First-Degree Relatives of Essential Tremor Cases: Evidence of Dietary Modification Before Disease Onset. ( 29953981 )
2018
3
Fragile X syndrome and fragile X-associated tremor ataxia syndrome. ( 29325626 )
2018
4
An In-Laboratory Validity and Reliability Tested System for Quantifying Hand-Arm Tremor in Motions. ( 29432113 )
2018
5
Deep Brain Stimulation Management of Essential Tremor with Dystonic Features. ( 29971197 )
2018
6
Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients. ( 29908405 )
2018
7
Unilateral Left Deep Brain Stimulation of the Caudal Zona Incerta Is Equally Effective on Voice Tremor as Bilateral Stimulation: Evidence from 7 Patients with Essential Tremor. ( 29975951 )
2018
8
Head and hand tremor measurement and analysis for the differentiation between essential and dystonic tremors. ( 29970277 )
2018
9
The effects of Thalamic Deep Brain Stimulation on speech dynamics in patients with Essential Tremor: An articulographic study. ( 29360867 )
2018
10
Hands train the brain-what is the role of hand tremor and anxiety in undergraduate microsurgical skills? ( 29968093 )
2018
11
A Treatable Rare Cause of Progressive Ataxia and Palatal Tremor. ( 29971195 )
2018
12
Tremor in motor neuron disease may be central rather than peripheral in origin. ( 29953699 )
2018
13
Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. ( 28298022 )
2018
14
White matter measures correlate with essential tremor severity-A pilot diffusion tensor imaging study. ( 29964316 )
2018
15
Clinical response to Vim's thalamic stereotactic radiosurgery for essential tremor is associated with distinctive functional connectivity patterns. ( 29335882 )
2018
16
Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report. ( 29582178 )
2018
17
Comparative Burden of Subclinical Tremor in a Cohort of Normal Individuals Stratified by Familial Risk for Essential Tremor. ( 29339654 )
2018
18
A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation. ( 29307012 )
2018
19
Essential tremor: "Plus" or "Minus". Perhaps now is the time to adopt the term "the essential tremors". ( 29937098 )
2018
20
Hand Tremor Questionnaire: A Useful Screening Tool for Differentiating Patients with Hand Tremor between Parkinson's Disease and Essential Tremor. ( 29971978 )
2018
21
Dysgeusia in deep brain stimulation for essential tremor. ( 29402567 )
2018
22
Pretherapeutic motor thalamus resting-state functional connectivity with visual areas predicts tremor arrest after thalamotomy for essential tremor: tracing the cerebello-thalamo-visuo-motor network. ( 29920392 )
2018
23
Fragile X-Associated Tremor/Ataxia Syndrome: Unmet Needs and a Path for the Future. ( 29951081 )
2018
24
Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome. ( 29885986 )
2018
25
Letter to the Editor. Magnetic resonance-guided focused ultrasound and essential tremor. ( 29961391 )
2018
26
Long Trace Eyeblink Conditioning Is Largely Preserved in Essential Tremor. ( 29916048 )
2018
27
Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. ( 29350074 )
2018
28
Age- and CGG Repeat-Related Slowing of Manual Movement in Fragile X Carriers: A Prodrome of Fragile X-Associated Tremor Ataxia Syndrome? ( 29389022 )
2018
29
Shaky and unsteady: Dynamic posturography in essential tremor. ( 29406890 )
2018
30
Detection of atypical porcine pestivirus in Brazil in the central nervous system of suckling piglets with congenital tremor. ( 29393592 )
2018
31
Effects on cognition and quality of life with unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 29385928 )
2018
32
Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson's disease motor subtypes. ( 29450651 )
2018
33
Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor. ( 29423509 )
2018
34
Directional communication during movement execution interferes with tremor in Parkinson's disease. ( 29427344 )
2018
35
Thalamic Deep Brain Stimulation Salvages Failed Focused Ultrasound Thalamotomy for Essential Tremor: A Case Report. ( 29433124 )
2018
36
Is staged bilateral thalamic radiosurgery an option for otherwise surgically ineligible patients with medically refractory bilateral tremor? ( 28387629 )
2018
37
Infantile Tremor Syndrome: Response to B12 Therapy. ( 29422355 )
2018
38
Pharmacological characterization of nicotine-induced tremor: Responses to anti-tremor and anti-epileptic agents. ( 29945769 )
2018
39
A Novel Posture for Better Differentiation Between Parkinson's Tremor and Essential Tremor. ( 29867328 )
2018
40
Association study of essential tremor genetic loci in Parkinson'sA disease. ( 29398123 )
2018
41
Jaw tremor: a manifestation of vascular parkinsonism? - a case report. ( 29960586 )
2018
42
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor. ( 29408817 )
2018
43
Tremor: Sorting Through the Differential Diagnosis. ( 29431985 )
2018
44
Inferior Olivary nucleus degeneration does not lessen tremor in essential tremor. ( 29372062 )
2018
45
Essential tremor. ( 29325613 )
2018
46
DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial. ( 29970404 )
2018
47
A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. ( 29385917 )
2018
48
Conditions Associated with Essential Tremor in Veterans: A Potential Role for Chronic Stress. ( 29971194 )
2018
49
Validating the targets for neurostimulation in essential tremor. ( 29970402 )
2018
50
Cerebellar and brainstem functional abnormalities in patients with primary orthostatic tremor. ( 29633401 )
2018
Sources

Variations for Tremor

About this section

ClinVar genetic disease variations for Tremor:

6
(show all 21)
# Gene Variation Type Significance SNP ID Assembly Location
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
2 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh38 Chromosome 8, 93795970: 93795970
3 GBA NM_001005741.2(GBA): c.1093G> A (p.Glu365Lys) single nucleotide variant risk factor rs2230288 GRCh37 Chromosome 1, 155206167: 155206167
4 GBA NM_001005741.2(GBA): c.1093G> A (p.Glu365Lys) single nucleotide variant risk factor rs2230288 GRCh38 Chromosome 1, 155236376: 155236376
5 C19orf12 NM_001031726.3(C19orf12): c.205G> A (p.Gly69Arg) single nucleotide variant Pathogenic rs515726205 GRCh37 Chromosome 19, 30193873: 30193873
6 C19orf12 NM_001031726.3(C19orf12): c.205G> A (p.Gly69Arg) single nucleotide variant Pathogenic rs515726205 GRCh38 Chromosome 19, 29702966: 29702966
7 LOC101927919; NUS1; SLC35F1 NC_000006.12 deletion Pathogenic GRCh37 Chromosome 6, 117961791: 118280044
8 LOC101927919; NUS1; SLC35F1 NC_000006.12 deletion Pathogenic GRCh38 Chromosome 6, 117640628: 117958881
9 LOC101927919; NUS1 NC_000006.12 deletion Pathogenic GRCh37 Chromosome 6, 117971549: 118218720
10 LOC101927919; NUS1 NC_000006.12 deletion Pathogenic GRCh38 Chromosome 6, 117650386: 117897557
11 covers 24 genes, none of which curated to show dosage sensitivity NC_000006.11 deletion Pathogenic GRCh37 Chromosome 6, 116681080: 119775014
12 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255
13 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh37 Chromosome 8, 94798483: 94798483
14 MPZ NM_000530.7(MPZ): c.699T> G (p.Ser233Arg) single nucleotide variant Likely pathogenic rs1057518839 GRCh38 Chromosome 1, 161305924: 161305924
15 MPZ NM_000530.7(MPZ): c.699T> G (p.Ser233Arg) single nucleotide variant Likely pathogenic rs1057518839 GRCh37 Chromosome 1, 161275714: 161275714
16 GLI2 NM_005270.4(GLI2): c.2644A> T (p.Thr882Ser) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 121746134: 121746134
17 GLI2 NM_005270.4(GLI2): c.2644A> T (p.Thr882Ser) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 120988558: 120988558
18 ADGRV1 NM_032119.3(ADGRV1): c.5188A> T (p.Ile1730Phe) single nucleotide variant Uncertain significance GRCh38 Chromosome 5, 90675320: 90675320
19 ADGRV1 NM_032119.3(ADGRV1): c.5188A> T (p.Ile1730Phe) single nucleotide variant Uncertain significance GRCh37 Chromosome 5, 89971137: 89971137
20 CACNA1H NM_021098.2(CACNA1H): c.6884C> T (p.Ser2295Phe) single nucleotide variant Uncertain significance rs772718469 GRCh37 Chromosome 16, 1270816: 1270816
21 CACNA1H NM_021098.2(CACNA1H): c.6884C> T (p.Ser2295Phe) single nucleotide variant Uncertain significance rs772718469 GRCh38 Chromosome 16, 1220816: 1220816

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion FAM129B Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor
Sources

Expression for Tremor

About this section
Search GEO for disease gene expression data for Tremor.
Sources

Pathways for Tremor

About this section

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.63 CNTN2 FMR1 LRRK2 MAPT PRKN SNCA
2
Parkinsons Disease Pathway 1
11.18 HTRA2 LRRK2 PRKN SNCA
3
Alpha-synuclein signaling 1
10.66 PRKN SNCA
Sources

GO Terms for Tremor

About this section

Cellular components related to Tremor according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.99 C19orf12 HTRA2 LRRK2 MAPT PRKN SNCA
2 cell projection GO:0042995 9.89 DRD3 FMR1 LRRK2 MAPT TENM4
3 synapse GO:0045202 9.83 CNTN2 FMR1 LRRK2 SNCA
4 dendrite GO:0030425 9.78 FMR1 FUS LRRK2 MAPT
5 axon GO:0030424 9.65 CNTN2 FMR1 LRRK2 MAPT SNCA
6 mitochondrial membrane GO:0031966 9.63 C19orf12 HTRA2 LRRK2
7 dendritic spine GO:0043197 9.61 FMR1 FUS MAPT
8 perikaryon GO:0043204 9.54 FMR1 FUS LRRK2
9 postsynapse GO:0098794 9.5 FMR1 LRRK2 SNCA
10 growth cone GO:0030426 9.46 FMR1 LRRK2 MAPT SNCA
11 neuron projection GO:0043005 9.43 CNTN2 FMR1 LRRK2 MAPT PRKN TENM4
12 inclusion body GO:0016234 9.4 LRRK2 SNCA
13 neuronal cell body GO:0043025 9.1 CNTN2 FMR1 FUS LRRK2 MAPT SNCA
14 membrane GO:0016020 10.28 C19orf12 CNTN2 DNAJC13 DRD3 FMR1 GBA

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 neuron projection development GO:0031175 9.83 CNTN2 GBA MAPT
2 response to oxidative stress GO:0006979 9.81 C19orf12 LRRK2 PRKN
3 cellular response to oxidative stress GO:0034599 9.78 HTRA2 LRRK2 SNCA
4 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.76 GBA LRRK2 PRKN
5 autophagy GO:0006914 9.76 C19orf12 DRD3 LRRK2 PRKN
6 negative regulation of protein phosphorylation GO:0001933 9.75 LRRK2 PRKN SNCA
7 regulation of autophagy GO:0010506 9.74 LRRK2 MAPT PRKN
8 learning GO:0007612 9.73 CNTN2 DRD3 PRKN
9 neuron development GO:0048666 9.72 FMR1 HTRA2 TENM4
10 adult locomotory behavior GO:0008344 9.69 HTRA2 PRKN SNCA
11 response to cocaine GO:0042220 9.68 DRD3 SNCA
12 positive regulation of neuron death GO:1901216 9.68 MAPT SNCA
13 regulation of canonical Wnt signaling pathway GO:0060828 9.67 LRRK2 PRKN
14 adult walking behavior GO:0007628 9.67 CNTN2 HTRA2
15 regulation of multicellular organism growth GO:0040014 9.67 DRD3 HTRA2
16 mitochondrion organization GO:0007005 9.67 GBA HTRA2 LRRK2 PRKN
17 regulation of reactive oxygen species metabolic process GO:2000377 9.66 PRKN SNCA
18 behavioral response to cocaine GO:0048148 9.66 DRD3 SNCA
19 regulation of neuronal synaptic plasticity GO:0048168 9.65 CNTN2 SNCA
20 regulation of neuron death GO:1901214 9.65 LRRK2 SNCA
21 positive regulation of proteasomal protein catabolic process GO:1901800 9.64 FMR1 PRKN
22 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.64 LRRK2 PRKN
23 cellular protein catabolic process GO:0044257 9.63 HTRA2 PRKN
24 microglial cell activation GO:0001774 9.62 MAPT SNCA
25 cellular response to dopamine GO:1903351 9.62 LRRK2 PRKN
26 supramolecular fiber organization GO:0097435 9.61 MAPT SNCA
27 intracellular distribution of mitochondria GO:0048312 9.6 LRRK2 MAPT
28 regulation of mitochondrial fission GO:0090140 9.59 LRRK2 MAPT
29 regulation of dopamine secretion GO:0014059 9.58 DRD3 PRKN SNCA
30 cellular response to manganese ion GO:0071287 9.54 LRRK2 PRKN
31 dopamine uptake involved in synaptic transmission GO:0051583 9.52 PRKN SNCA
32 regulation of neurotransmitter secretion GO:0046928 9.5 FMR1 PRKN SNCA
33 protein localization to mitochondrion GO:0070585 9.49 LRRK2 PRKN
34 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 DRD3 LRRK2
35 regulation of synaptic vesicle transport GO:1902803 9.43 LRRK2 PRKN
36 synaptic transmission, dopaminergic GO:0001963 9.43 DRD3 PRKN SNCA
37 dopamine metabolic process GO:0042417 9.33 DRD3 PRKN SNCA
38 regulation of locomotion GO:0040012 9.13 DRD3 LRRK2 SNCA
39 negative regulation of neuron death GO:1901215 9.02 GBA HTRA2 LRRK2 PRKN SNCA

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.46 FMR1 LRRK2 MAPT SNCA
2 Hsp70 protein binding GO:0030544 9.37 PRKN SNCA
3 dynein complex binding GO:0070840 9.32 FMR1 SNCA
4 phospholipase binding GO:0043274 9.26 PRKN SNCA
5 identical protein binding GO:0042802 9.23 CNTN2 FMR1 FUS HTRA2 LRRK2 MAPT
6 tubulin binding GO:0015631 9.13 LRRK2 MAPT PRKN
Sources

Sources for Tremor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....